Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
CURRENT EVIDENCE TO DIAGNOSE AND TREAT GEP-NENS
Rocio Garcia-Carbonero
Medical Oncology Department
Hospital Universitario 12 de Octubre
Universidad Complutense de Madrid
MEDICAL ONCOLOGIST (METASTATIC DISEASE)
DISCLOSURE OF INTEREST
• Travel and educational support from Ipsen, Pfizer, Novartis, Roche, Merck.
• Advisory/Speaker honoraria from Ipsen, Pfizer, Novartis, AAA, Roche, Merck, MSD, Sanofi,
Bayer, Lilly, PharmaMar, BMS, Servier.
• Research support from Pfizer and BMS.
CLINICAL SCENARIO
✓ Stage: Advanced unresectable disease
✓ Proliferative index (Ki67): G2-G3 (Ki-67 3-100%)
✓ Therapeutic aim: Antiproliferative treatment/Tumor control
✓ Type of therapy: Systemic therapy (SSA, PRRT, CT, TT)
Baseline Assessment To Select an Optimal Therapeutic Strategy
Patient assessment
• Symptom assessment
• Performance status
• Age and comorbidities
• Family & social support
• Needs and aims
Tumor assessment
• Histological assessment
• Biochemistry
• CT / MR scan
• 68Ga PET / octreotide scan
Factors to consider
• Primary tumor site
• Tumor differentiation
• Proliferation rate (Ki-67)
• Tumor growth rate
• TNM stage
• Organs involved (liver
dominant disease?)
• Functional assessment
• Symptom & tumor burden
• Toxicity profiles
• Prior therapies
Treatment options
• Surgery
• Biological therapy
• Targeted therapy
• PRRT
• Chemotherapy
• Loco-regional therapy
Primary tumor site: prognostic and predictive implications
RectumAppendixStomachColonSmall intestineLungCecumPancreasLiver
Survival by Tumor Site
➢ PRRT: greater ORR in PNETs vs GI-NETs in non-controlled trials; RCT only conducted in midgut NETs
➢ Sunitinib: efficacy only demonstrated in PNETs (RCT)
➢ Chemotherapy: greater ORR in PNETs vs GI-NETs in non-controlled trials; greater ORR in G3 NECs vs NETs
Proliferation rate is really a continuous variable
Nuñez-Valdovinos B,..Garcia-Carbonero R. RGETNE. Oncologist 2018
Tumor differentiation and proliferation rates are related
but independent prognostic variables
Heetfeld et al, ERC 2015
Ki-67 values are generally lowerfor NETs vs NECsbut there is no absolute cutoffvalue to helpdiscriminate bothentities.
Ki-67 index in G3 NET vs NEC
NEC type A: NEC Ki-67>55%
NEC type B: NEC Ki-67 20-55%
NEC type C: NET Ki-67 20-55%
Milione et al, Neuroendocrinol 2017
Molecular features can help discriminate NET vs NEC
Coriat et al, The Oncologist 2016
Proliferation rate influences treatment response
NORDIC NEC Study
Sorbye et al, Ann Oncol 2013
✓ All CT-treated patients: ORR 31% OS 11 months (vs 1 month for BSC)
✓ Patients with Ki-67 < 55% had a lower response rate (15% vs 42%, P<.001), but better
survival (14 vs 10 months, p<.001) than patients with Ki-67>55%
✓ Negative prognostic factors for OS: poor PS, colorectal primary, platelets or LDH levels
Ki-67 < 55%
Ki-67 > 55%
Pancreatic
Colorectal
Tumor differentiation influences treatment response
Heetfeld et al, ERC 2015
Overall survival
✓NET G3: 99 months
✓NEC G3: 17 months
SSTR tumor expression
• Diagnostic implications: SSTR imaging (octreoscan, Ga68-PET)
✓ Localization of primary tumor
✓ Extent of disease
✓Confirms the NE nature of the tumor
• Prognostic significance: favorable
• Therapeutic implications:
✓ Selection of patients for treatment with “cold” SSA
✓ Selection of patients for treatment with PRRT (SSA-Radioisotope)
✓Assessment of response to PRRT
Other prognostic / predictive factors
TRASGU Study (nomogram to predict PFS in SSA-treated advanced NETs)
Garcia-Carbonero R, RGETNE, ESMO 2018
NOMOGRAM
http://www.iricom.es/prognostictools/Trasgu
Other prognostic / predictive factors
GI NEC Score
Lamarca et al, JNCI 2017
19.4 m vs 5.2 m
Drug- and treatment-related issues
Patient´s features: PS, age, comorbidity, preferences
Drug issues: safety profile, availability, convenience, cost
Therapeutic objective:
✓ induce tumor shrinkage
❖ to facilitate resection
❖ to control functional syndrome
❖ to control symptoms related to tumor burden
✓ slow tumor progression / improve survival?
✓ improve/maintain quality of life
But we should not forget…..
✓ Clinical judgement – our real patients are often far from the ideal patients of clinical
trials – don’t forget we are doctors !!
✓ Biology is complex – NEN is a very heterogenous family of diseases and we need to
understand them better
Endocrinol Metab Clin North Am. 2018;47:683
TAKE HOME MESSAGE
NET NEC
Ki-67 <10% 11-20% 21-55% 21-55% >55%
SSA ++
PRRT ++ ++ +
Sunitinib* ++ ++ +
Everolimus ++ ++ +
Tem-Cap + ++ +
Platinum-based ++ ++
* Pancreatic primary
✓ Include all factors in the equation – far beyond tumor diff and Ki-67
✓ Multidisciplinary expert care is key